Melatonin level as a risk factor for age-related macular degeneration

Background. The current trend towards an increase in age-related macular degeneration (AMD) incidence rate in the population, including the working-age population, with a possible loss of professional activity, indicates the need for early preclinical identification of risk groups, timely prevention and treatment. In the prevention and treatment of AMD, the prospect of using melatonin is being actively discussed.

Aim: to analyze serum and tear fluid levels of melatonin in patients with AMD and study their correlation with risk factors.

Materials and methods. In the course of the study, two groups were formed: the main group - patients with non-exudative AMD and senile cataract (n = 40) and the reference group - conditionally healthy patients without AMD and cataract (n = 20). Patients of both groups were surveyed to identify risk factors for AMD. The content of melatonin in blood serum and lacrimal fluid was determined by enzyme-linked immunosorbent assay using the Melatonin ELISA Kit (USA).

Results. In the course of the study, it was found that the concentration of melatonin in blood serum and tear fluid in patients with AMD was significantly lower than in patients of the reference group (p <0.05). Serum and tear fluid melatonin levels depend on the following factors: age, body mass index (BMI), arterial hypertension, eye color, insomnia, and night work. It is possible that the local determination of melatonin in the lacrimal fluid can be a biomarker in the determination of ophthalmic pathological conditions.

Conclusion. The obtained results can be used as recommendations for clarifying individual regimens for the use of melatonin, especially in the treatment of patients with AMD.

1. Prevention of Blindness and Visual Impairment: Priority Eye Diseases. Geneva: World Health Organization; 2004. Available from: http://www.who.int/blindness/causes/priority/en. [Accessed 8th December 2020]

2. Lu L, Hackett SF, Mincey A, Lai H, Campochiaro PA. Effects of Different Types of Oxidative Stress in RPE Cells. J Cell Physiol. 2006; 206 (1): 119–125. doi: 10.1002/jcp.20439

3. Coleman HR, Chan CC, Ferris III FL, Chew EY. Age-related macular degeneration. Lancet. 2008; 372 (9652): 1835–1845. doi: 10.1016/S0140–6736 (08) 61759–6

4. Roubeix С, Sahel JA, Guillonneau X, Delarasse S, Sennlaub F. On the inflammatory origins of AMD. Med Sci (Paris). 2020; 36 (10): 886–892. doi: org/10.1051/medsci/2020159

5. Alkozi HA, Wang X, Perez de Lara MJ, Pintor J. Presence of melanopsin in human crystalline lens epithelial cells and its role in melatonin synthesis. Exp Eye Res. 2017; 154:168–176. doi: 10.1016/j.exer.2016.11.019

6. Crooke A, Huete-Toral F, Martínez-Águila A, Colligris B, Pintor J. Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential. Expert Opin Drug Discov. 2012; 7 (10): 989–1001. doi: 10.1517/17460441.2012.714769

7. Gaspar do Amaral F, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch. Endocrinol. Metab. 2018. 62 (4): 472–479. doi: 10.20945/2359–3997000000066

8. Fernández A, Ordóñez R, Reiter RJ, González-Gallego J, Mauriz JL. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J Pineal Res. 2015; 59 (3): 292–307. doi: 10.1111/jpi.12264

9. Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci. 2017;74 (21): 3863–3881. doi: 10.1007/s00018-017-2609-7

10. Carrascal L, Nunez-Abades P, Ayala A, Cano M. Role of Melatonin in the Inflammatory Process and its Therapeutic Potential. Curr Pharm Des. 2018; 24 (14): 1563–1588. doi: 10.2174/1381612824666180426112832

11. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem. 2002;2 (2): 167–179. doi: 10.2174/1568026023394335

12. Pierpaoli W, Maestroni GJ. Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects. Immunol Lett. 1987; 16 (3-4):355–361. doi: 10.1016/0165-2478 (87) 90169-6

13. Kaur C, Sivakumar V, Robinson R, Foulds WS, Luu CD, Ling EA. Neuroprotective effect of melatonin against hypoxiainduced retinal ganglion cell death in neonatal rats. J. Pineal Res. 2013; 54 (2):190–206. doi: 10.1111/jpi.12016

14. Stefanova NA, Zhdankina AA, Fursova AZh, Kolosova NG. Potential of melatonin for prevention of age-related macular degeneration: experimental study. Adv Gerontol 2013; 26: 122–129 (in Russ)

15. Zetner D, Andersen LP, Rosenberg J. Melatonin as protection against radiation injury: a systematic review. Drug Res (Stuttg). 2016; 66 (6):56–57. doi: 10.1055/s-0035–1569358

16. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin’s role in antiaging mechanisms. J. Pineal Res. 2013; 55 (4):325–356. doi: 10.1111/jpi.12090

17. Lv XD, Liu S, Cao Z, Gong LL, Feng XP, Gao QF, et. al. Correlation between serum melatonin and aMT6S level for age-related macular degeneration patients. Eur Rev Med Pharmacol Sci. 2016; 20 (20): 4196–4201

18. Rosen R, Hu DN, Perez V, Tai K, Yu GP, Chen M, et. al. Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients. Mol Vis. 2009; 21 (15): 1673–1679

19. Changxian Yi, Pan X, Yan H, Guo M, Pierpaoli W. Effects of Melatonin in Age-Related Macular Degeneration. Ann. N. Y. Acad. Sci. 2005; 1057: 384–392. doi: 10.1196/annals. 1356.029.

20. Kandel H, Pesudovs K, Watson SL. Measurement of Quality of Life in Keratoconus. Cornea. 2020; 39 (3): 386–393. doi: 10.1097/ICO.0000000000002170

21. Carracedo G, Carpena C, Concepción P, Díaz V, GarcíaGarcíac M, Jemni N, et. al. Presence of melatonin in human tears. Journal of Optometry. 2017;10 (1):3–4. doi.org/10.1016/j.optom.2016.03.002

22. Stepicheva NA, Weiss J, Shang P, Yazdankhah M, Ghosh S, Bhutto IA, et. al. Melatonin as the Possible Link Between Age-Related Retinal Regeneration and the Disrupted Circadian Rhythm in Elderly. Adv Exp Med Biol. 2019; 1185:45–49. doi: 10.1007/978-3-030-27378-1_8

23. Crooke A, Huete‐Toral F, Colligris B, Pintor J. The role and therapeutic potential of melatonin in age‐related ocular diseases. J. Pineal Res. 2017; 63 (2). doi: 10.1111/jpi.12430

24. Mehta S. Age-Related Macular Degeneration. Prim Care. 2015;42 (3):377–391. doi: 10.1016/j.pop.2015.05.009

25. Momeni-Moghaddam H, Kundart J, Ehsani M, AbdehKykha A. Body mass index and binocular vision skills. Saudi J Ophthalmol. 2012;26 (3):331–334. doi:10.1016/j.sjopt.2012.01.002

26. Haas P, Kubista KE, Krugluger W, Huber J, Binder S. Impact of visceral fat and pro-inflammatory factors on the pathogenesis of age-related macular degeneration. Acta Ophthalmol. 2015; 93 (6): 533–538. doi: 10.1111/aos.12670

27. Tokarz P, Kaarniranta K, Blasiak J. Role of antioxidant enzymes and small molecular weight antioxidants in the pathogenesis of age-related macular degeneration (AMD). Biogerontology. 2013; 14 (5): 461–482. doi: 10.1007/s10522-013-9463-2

28. Bovier ER, Lewis RD, Hammond BR Jr. The relationship between lutein and zeaxanthin status and body fat. Nutrients. 2013; 5 (3): 750–757. doi: 10.3390/nu5030750

29. Lipecz A, Miller L, Kovacs I, Czakó C, Csipo T, Baffi J, et. al. Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. Geroscience. 2019;41 (6):813–845. doi: 10.1007/s11357-019-00138-3

30. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS. Effect of systemic hypertension on foveolar choroidal blood flow in age related macular degeneration. Br J Ophthalmol. 2006; 90 (3): 342–346. doi: 10.1136/bjo.2005.082974

31. Thomas J, Mohammad S, Charnigo R, Baffi J, Abdel-Latif A, Ziada KM. Age-Related Macular Degeneration and Coronary Artery Disease in a VA Population. South Med J. 2015; 108 (8): 502–506. doi: 10.14423/SMJ.0000000000000329

32. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy. The Blue Mountains Eye Study. Ophthalmology. 1998;105 (8): 1359–63. doi: 10.1016/S0161-6420(98)98013-7

33. Higuchi S, Motohashi Y, Ishibashi K, Maeda T. Influence of eye colors of Caucasians and Asians on suppression of melatonin secretion by light. Am J Physiol Regul Integr Comp Physiol. 2007; 292 (6): 2352–2356. doi.org/10.1152/ajpregu.00355.2006

34. Tsai DC, Chen HC, Leu HB, Chen SJ, Hsu NW, Huang CC, et. al. The association between clinically diagnosed insomnia and age‐related macular degeneration: a population‐based cohort study. Acta Ophthalmol. 2020; 98 (2). e238-e244. doi: 10.1111/aos.14238